Daiichi Sankyo Co., LTD.a : Daiichi Sankyo Launches Silodosin for the Treatment of Dysuria in China

Daiichi Sankyo Company Limited today announced that its subsidiary, Daiichi Sankyo Pharmaceutical Co., Ltd., has begun marketing silodosin , which was developed for treatment of dysuria associated with benign prostatic hyperplasia.

http://www.europeaninvestor.com/SiteFiles/company/company.asp?Customer=1&CompanyCode=JP-D4S&PressID=1532698&MenuItem=91&wtlang=english